Mavrilimumab
HM20019145
Phase 2 small_molecule completed
Quick answer
Mavrilimumab for COVID-19 is a Phase 2 program (small_molecule) at Kiniksa Pharmaceuticals International, plc with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Kiniksa Pharmaceuticals International, plc
- Indication
- COVID-19
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed